<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377856</url>
  </required_header>
  <id_info>
    <org_study_id>KMUH-IRB-960056</org_study_id>
    <secondary_id>KMUH</secondary_id>
    <nct_id>NCT02377856</nct_id>
  </id_info>
  <brief_title>Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection</brief_title>
  <official_title>Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with acute hepatitis C virus (HCV) infection usually become chronicity if viremia&#xD;
      persists after 6 months of infection. The result of using pegylated interferon plus ribavirin&#xD;
      combination therapy upon these patients remains to be explored&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combination therapy with pegylated interferon-alpha plus ribavirin has greatly improved the&#xD;
      treatment efficacy and is the mainstream of treatment for chronic hepatitis C infection.&#xD;
      Current guideline suggests pegylated interferon monotherapy for patients with acute HCV&#xD;
      infection. The efficacy might greatly improves if the treatment starts earlier. An estimation&#xD;
      of 20 percents of patients could recover from acute infection spontaneously within 6 months&#xD;
      after exposure,however. The present study aims to clarify the efficacy of pegylated&#xD;
      interferon and ribavirin combination therapy for patients with hepatitis C six months after&#xD;
      onset of acute infection&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment efficacy in terms of SVR rate</measure>
    <time_frame>1.5 yr</time_frame>
    <description>Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety issues regarding adverse events</measure>
    <time_frame>1.5 yrs</time_frame>
    <description>patient safety of pegylated interferon and ribavirin combination therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acute Hepatitis C</condition>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 patients will receive pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks combination treatment, followed by 24 weeks of follow-up. 'pegylated interferon alpha 2a, ribavirin'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>40 patients without treatment will be followed for the clinical course for 1.5 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon alpha 2a, ribavirin</intervention_name>
    <description>pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks</description>
    <arm_group_label>intervention</arm_group_label>
    <other_name>PEGASYSÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients 18-80 years of age&#xD;
&#xD;
          -  Patients have never been treated with traditional interferon plus ribavirin or&#xD;
             peginterferon plus ribavirin&#xD;
&#xD;
          -  Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test&#xD;
&#xD;
          -  Detectable serum HCV-RNA for &gt; 6 months&#xD;
&#xD;
          -  Compensated liver disease&#xD;
&#xD;
          -  Negative urine or blood pregnancy test (for women of childbearing potential)&#xD;
             documented within the 24-hour period prior to the first dose of study drug&#xD;
&#xD;
          -  All fertile males and females receiving ribavirin must be using two forms of effective&#xD;
             contraception during treatment and during the 6 months after treatment end&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with ongoing pregnancy or breast feeding&#xD;
&#xD;
          -  Present therapy with any systemic anti-neoplastic or immunomodulatory treatment&#xD;
             (including supraphysiologic doses of steroids and radiation) within 6 months prior to&#xD;
             the first dose of study drug&#xD;
&#xD;
          -  Any investigational drug 6 weeks prior to the first dose of study drug&#xD;
&#xD;
          -  Co-infection with active hepatitis A, hepatitis B and/or human immunodeficiency virus&#xD;
             (HIV)&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease,&#xD;
             alcoholic liver disease, toxin exposures)&#xD;
&#xD;
          -  Clinical evidence or history of hepatocellular carcinoma&#xD;
&#xD;
          -  History or other evidence of bleeding from esophageal varices or other conditions&#xD;
             consistent with decompensated liver disease&#xD;
&#xD;
          -  Neutrophil count &lt;1500 cells/mm3 or platelet count &lt;90,000 cells/mm3 at screening&#xD;
&#xD;
          -  Serum creatinine level &gt;1.5 times the upper limit of normal at screening&#xD;
&#xD;
          -  History of severe psychiatric disease, especially depression. Severe psychiatric&#xD;
             disease is defined as treatment with an antidepressant medication or a major&#xD;
             tranquilizer at therapeutic doses for major depression or psychosis, respectively, for&#xD;
             at least 3 months at any previous time or any history of the following: a suicidal&#xD;
             attempt, hospitalization for psychiatric disease, or a period of disability due to a&#xD;
             psychiatric disease&#xD;
&#xD;
          -  History of a severe seizure disorder or current anticonvulsant use&#xD;
&#xD;
          -  History of immunologically mediated disease, chronic pulmonary disease associated with&#xD;
             functional limitation, severe cardiac disease, major organ transplantation or other&#xD;
             evidence of severe illness, or any other conditions which would make the patient, in&#xD;
             the opinion of the investigator, unsuitable for the study&#xD;
&#xD;
          -  History of thyroid disease poorly controlled on prescribed medications, elevated&#xD;
             thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to&#xD;
             thyroid peroxidase and any clinical manifestations of thyroid disease&#xD;
&#xD;
          -  Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration)&#xD;
&#xD;
          -  Evidence of drug abuse (including excessive alcohol consumption&gt;40 g/day) within one&#xD;
             year of study entry&#xD;
&#xD;
          -  Inability or unwillingness to provide informed consent or abide by the requirements of&#xD;
             the study&#xD;
&#xD;
          -  Male partners of women who are pregnant&#xD;
&#xD;
          -  Hgb &lt;11 g/dL in women or &lt;12 g/dL in men at screening&#xD;
&#xD;
          -  Any patient with major thalassemia&#xD;
&#xD;
          -  Patients with documented or presumed coronary artery disease or cerebrovascular&#xD;
             disease should not be enrolled if, in the judgment of the investigator, an acute&#xD;
             decrease in hemoglobin by up to 4 g/dL (as may be seen with ribavirin therapy) would&#xD;
             not be well-tolerated&#xD;
&#xD;
          -  Local or Systemic malignancy unstable status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Lung Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>September 9, 2014</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <last_update_submitted>February 29, 2016</last_update_submitted>
  <last_update_submitted_qc>February 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Medical University Chung-Ho Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Ming-Lung Yu</investigator_full_name>
    <investigator_title>MD. PhD.</investigator_title>
  </responsible_party>
  <keyword>acute hepatitis C</keyword>
  <keyword>treatment</keyword>
  <keyword>SVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

